The clock is ticking in Mainz. BioNTech has handed the chief executive role to Guido Oelkers through February 2027, tasking him with steering the company’s cancer therapies toward their first market approvals. It is a leadership change that lands at the most expensive strategic pivot in the company’s history — and the market is watching closely.
Shares are changing hands at roughly 78–79 euros, having shed nearly a fifth of their value over the past twelve months. The stock sits more than a quarter below its 52-week high of 105.80 euros, a gap that reflects how far investor sentiment has shifted. BioNTech is no longer priced as a pandemic-era vaccine champion; it is now a binary bet on whether an ambitious oncology pipeline can deliver before the money runs out.
A Forecast Cut That Speaks Volumes
The most immediate pressure point is revenue. BioNTech now guides for 2026 sales of just 1.6 to 1.9 billion euros, a sharp reduction from the 2 to 2.3 billion euro range management floated back in March. The culprit is the continued collapse in global demand for COVID-19 shots. German inventory rules compound the problem: existing vaccine stockpiles can still be administered during the 2026 season, which suppresses fresh orders. A milestone payment the company had previously counted on has also been dropped from the outlook.
Research and development spending is being trimmed in tandem — to 2.0 to 2.3 billion euros from an earlier target of 2.2 to 2.5 billion — but that still leaves the company spending more on science than it brings in from sales. The first half of 2026 closed with a loss in the billions, underscoring just how far the COVID franchise has fallen.
There is one near-term bright spot: the European Commission approved the updated COVID vaccine targeting the XFG variant on 3 August, a joint effort with Pfizer. BioNTech expects 613 million euros in third-quarter collaboration revenue from that partnership. But the approval offers a temporary lift, not a cure for the structural decline in vaccine demand.
The Pipeline Carries the Weight
With the vaccine business fading, the oncology portfolio has become the entire story. BioNTech is currently running 14 registration-enabling trials simultaneously, having kicked off six new Phase 3 studies in the first half of 2026 alone. Five of those are for Pumitamig — the antibody candidate formerly known as BNT327 — and one for the antibody-drug conjugate Elfetabart Drozuntecan.
Pumitamig, developed alongside Bristol Myers Squibb, is the company’s most closely watched asset. It is now enrolled in seven registration trials and showed encouraging efficacy in lung cancer across multiple PD-L1 expression levels at the ASCO congress in 2026. The fourth quarter brings a pivotal moment: the primary analysis of the Phase 3 DYNASTY-Breast02 study for BNT323 (Trastuzumab Pamirtecan), plus interim data on Gotistobart. Final recruitment figures from the ROSETTA Lung-02 trial are also expected before year-end.
Should investors sell immediately? Or is it worth buying BioNTech?
The company’s war chest of roughly 16.6 billion euros provides runway, but it is finite. With 14 parallel registration studies consuming cash, the central question is whether the data readouts arrive before the reserves are meaningfully depleted. The market capitalization of just under 19.9 billion euros hinges on that timing.
A Buyback, a Patent Fight, and a Chart That Looks Bruised
Management has taken steps to cushion the stock. A share repurchase program of up to one billion dollars runs through May 2027, which could provide support during volatile stretches. Analysts see upside too: the average price target stands at 107.15 euros, implying gains of nearly 37 percent from current levels.
But the bear case has ammunition of its own. In July 2026, Arbutus and Genevant filed three new lawsuits against BioNTech and Pfizer across multiple jurisdictions, targeting the lipid nanoparticle technology used in the mRNA vaccines. The patent dispute now runs on two fronts simultaneously, raising the prospect of hefty licensing fees or settlement payments down the line.
Technically, the stock remains under pressure. It trades roughly seven percent below its 200-day moving average of around 84.20–84.27 euros — a sign that the medium-term trend has not turned. The RSI sits at 45.4, suggesting neither oversold conditions nor bullish momentum, just an uneasy equilibrium.
What Happens Next
The fourth quarter will likely set the tone for the months ahead. If the Phase 3 analysis for BNT323 hits its efficacy targets, the oncology narrative gains real credibility and the first regulatory submissions in cancer come into view. A miss, however, would leave the stock exposed to further downside, with the distance to the 52-week low of 68.35 euros serving as a reference point for how much room there is to fall.
Two catalysts deserve particular attention before year-end: the ROSETTA Lung-02 recruitment data and any court rulings on the July patent claims. Both carry the potential to reshape the risk profile of the stock. For now, as long as the share price holds above that 68.35 euro floor, the setup favors stabilization — but the margin for error is thinning with every quarter that passes without a commercial breakthrough.
Ad
BioNTech Stock: Buy or Sell?! New BioNTech Analysis from August 5 delivers the answer:
The latest BioNTech figures speak for themselves: Urgent action needed for BioNTech investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from August 5.
BioNTech: Buy or sell? Read more here...
